Direct answer
No supplement reviewed here is proven to broadly prevent or cure cancer. Fiber and whole-grain food patterns are associated with lower colorectal cancer risk, while vitamin D’s advanced-cancer signal is preliminary. Curcumin and IV vitamin C findings depend on formulation, route and cancer regimen and do not establish general cures. Review every product with the oncology team; do not replace treatment with alternative remedies.
- The strongest ingredient-level evidence is for food, not pills: a dose-response meta-analysis found every 10 g/day increase in dietary fiber was associated with a 10% lower colorectal cancer risk (RR 0.90), and three daily servings of whole grains were linked to a 17% lower risk (RR 0.83).
- A WHO-commissioned review included 47 trials across several polyunsaturated-fat interventions. Its long-chain omega-3 analyses found little or no effect on cancer diagnosis (27 trials; RR 1.02, 95% CI 0.98–1.07) or cancer death (18 trials; RR 0.97, 95% CI 0.90–1.06).
- A 2023 review of seven heterogeneous curcumin trials, including an IV formulation and an oral precancer study, found the evidence insufficient to support routine cancer therapy, and Cochrane found green tea/EGCG evidence inconsistent and low-certainty, with extracts causing GI effects and liver-enzyme elevations in trials. (Curcumin review; Cochrane green tea review)
- Cochrane found no RCT evidence supporting laetrile/amygdalin ("vitamin B17," including apricot-kernel products) for cancer treatment, and judged the risk-benefit balance unambiguously negative because of cyanide poisoning risk.
- A 2016 BMJ Open review searching through April 2015 found no randomized trials and no alkaline-water cancer-treatment studies. Its historical search does not establish an exhaustive current absence of research.
The most evidence-supported “cancer ingredients” are not cancer-treatment pills: dietary fiber and whole grains are associated with lower colorectal cancer risk in prospective studies. Cruciferous-vegetable findings are observational and weaker in prospective cohorts; they do not establish a benefit from sulforaphane capsules (BMJ fiber meta-analysis, cruciferous vegetable meta-analysis). Vitamin D did not reduce overall invasive cancer incidence in the large VITAL randomized trial, although a secondary analysis reported an advanced-cancer signal that requires confirmation (VITAL primary trial, VITAL advanced-cancer analysis). Green tea, curcumin, and omega-3 are popular, but the reviews cited here do not establish broad supplement prevention. The curcumin review addresses therapy rather than a general-population prevention trial (Cochrane green tea review, curcumin RCT review, omega-3 randomized-trial meta-analysis). Laetrile/B17, apricot kernels, hydrogen peroxide or oxygen therapies, Gerson therapy, Essiac tea, graviola, and alkaline water should not replace oncology care; several have no controlled evidence and can cause serious harm (Cochrane laetrile review, NCI Gerson PDQ, BMJ Open alkaline-water review).
Table of Contents
- Evidence summary
- The cancer ingredient evidence map
- Foods and supplements: evidence for risk reduction
- Popular cancer ingredients that are unproven, debunked, or dangerous
- What works and what does not
- Side effects and interactions
- Funding and conflict review
- Frequently asked questions
- Sources
Evidence summary
| Claim | Best available evidence | Source country / scope | Funding and conflict check | Grade |
|---|---|---|---|---|
| Higher dietary fiber and whole-grain intake is associated with lower colorectal cancer risk. | Prospective-dose response meta-analysis: every 10 g/day increase in total dietary fiber was associated with RR 0.90 for colorectal cancer; three additional daily servings of whole grains were associated with RR 0.83. | International cohorts; UK-led analysis. | WCRF grant 2007/SP01 supported the review; authors declared no interested-organization financial relationships and stated the sponsor had no study/manuscript role. All cohort finances were not traced. | Strong for foods BMJ |
| Cruciferous vegetables may reduce colorectal cancer risk. | The pooled 35-study estimate was RR 0.82; the 11 prospective studies were weaker and borderline (RR 0.93, 95% CI 0.87–1.00), versus RR 0.74 in case-control studies. | International studies; China/US authorship. | Chinese public infectious-disease research grants and NIH/Fogarty training support were listed; authors declared no conflicts. Included-study finances were not exhaustively traced. | Moderate PMC |
| Sulforaphane supplements prevent cancer. | The cited 2007 review mainly discusses mechanisms and biomarkers; it does not establish supplement cancer-incidence or treatment benefit. | Global literature. | Academic narrative review. The available original manuscript does not provide a complete funding/conflict statement; underlying studies and product-supply terms were not fully traced. | Not proven as a supplement PMC |
| Vitamin D prevents cancer. | Vitamin D3 2,000 IU/day did not lower invasive cancer incidence in VITAL (HR 0.96; 95% CI 0.88–1.06). A secondary metastatic-or-fatal composite favored vitamin D (HR 0.83; 95% CI 0.69–0.99), without correction for multiple comparisons; confirmation is needed. Secondary analysis | United States randomized trial. | NIH-funded VITAL disclosed Pharmavite and Pronova/BASF agents/placebos/packaging and free Quest assays. The secondary paper also disclosed Buring’s spouse on Pharmavite’s scientific advisory board. Exact support amounts were not reported. | Mixed PubMed |
| Green tea or EGCG prevents cancer. | Cochrane found inconsistent results and low-certainty evidence; green-tea extracts caused gastrointestinal effects and liver-enzyme elevations in trials. | International review. | The review listed Pilkington Family Trusts, Deutsche Krebshilfe and Cochrane/ViFab support; authors declared no known interests. Included studies reported public funding, company supplies and an Ito En employee; complete financial chains remain unverified. | Inconclusive Cochrane/PMC |
| Curcumin slows or treats cancer. | Seven small, heterogeneous trials produced mixed hard-endpoint findings. The 2023 review did not support routine therapy; it included adjunct regimens, one IV formulation and oral leukoplakia, a precancer condition. | International review. | The review declared no external funding and no conflicts. Those declarations do not clear the included trials’ sponsors or product-supply terms. | Not proven PMC |
| Omega-3 supplements prevent cancer. | Among 47 trials of several PUFA interventions, the long-chain omega-3 analyses found little or no effect on cancer diagnosis (27 trials; RR 1.02, 95% CI 0.98–1.07) or cancer death (18 trials; RR 0.97, 95% CI 0.90–1.06). | International randomized trials. | WHO commissioned/funded the review and requested eligibility criteria and some analyses; authors disclosed WHO-funded work and meeting travel, with no interested-organization relationships declared. Included-trial finances remain incompletely traced. | Does not work for prevention British Journal of Cancer |
| Laetrile/B17/apricot kernels treat cancer. | Cochrane found no RCT or quasi-RCT evidence supporting laetrile/amygdalin and judged the risk-benefit balance unambiguously negative because of cyanide poisoning risk. | International review. | Listed support included NIHR/Cochrane infrastructure, European Commission CAM-Cancer and Deutsche Krebshilfe projects. Authors declared no direct financial interest; the listed funders reportedly had no review role. | Dangerous / do not use Cochrane/PMC |
| Alkaline water or alkaline diets treat cancer. | The 2016 review searched through April 2015 and found one observational acid-load study, no RCTs, and no alkaline-water cancer-treatment studies. | Canada-led review; global literature. | No specific grant; competing interests declared none. | No evidence BMJ Open |
Text version of this infographic
| Evidence level | Ingredients or approaches | Practical meaning |
|---|---|---|
| Strongest | Fiber-rich foods and whole grains | Prospective food-pattern associations with lower colorectal cancer risk; this is not proof for isolated fiber pills or treatment of existing cancer. |
| Weak / exploratory | Cruciferous vegetables; vitamin D advanced-cancer signal | Cruciferous findings are observational; the vitamin D composite is an unconfirmed secondary signal. Neither establishes cancer therapy or a subgroup-based dosing rule. |
| Inconclusive | Green tea beverage; sulforaphane capsules | Interesting biology and mixed epidemiology; cancer-prevention proof is not strong enough for supplement claims. |
| Avoid | B17/laetrile, apricot kernels, peroxide, Gerson therapy, Essiac | No good cancer-treatment evidence; several carry serious toxicity or treatment-delay risk. |
The cancer ingredient evidence map
Cancer is a leading cause of death worldwide, and WHO lists tobacco use, high body mass index, alcohol use, low fruit and vegetable intake, and lack of physical activity among major behavioral and dietary risks (WHO cancer fact sheet). IARC classifies processed meat as carcinogenic to humans and red meat as probably carcinogenic to humans, which means ingredient decisions should include what to reduce as well as what to add (IARC red and processed meat evaluation).
The evidence pattern is consistent: foods and dietary patterns have more credible cancer-prevention evidence than isolated “anticancer” supplement capsules. Randomized cancer-prevention trials are difficult because cancer develops over years, but RCTs are still essential when sellers claim a capsule prevents, slows, or treats cancer.
Text version of this infographic
| Category | What it means | Examples | Verdict |
|---|---|---|---|
| Risk reduction | Long-term dietary pattern associated with lower future cancer risk in populations. | Fiber-rich foods, whole grains, vegetables. | Useful as prevention support; not a treatment plan. |
| Treatment claim | A claim that an ingredient shrinks, cures, detoxes, alkalizes, or selectively kills cancer. | B17/laetrile, hydrogen peroxide/oxygen therapies, Gerson therapy. | Requires controlled oncology evidence; unsafe when used instead of proven care. |
Foods and supplements: evidence for risk reduction
1. Dietary fiber and whole grains
Verdict: STRONG OBSERVATIONAL ASSOCIATION for food patterns
Dietary fiber has strong prospective observational evidence in this review: a BMJ dose-response meta-analysis of prospective studies found RR 0.90 per 10 g/day higher total fiber intake and RR 0.83 per three daily servings of whole grains for colorectal cancer (BMJ fiber meta-analysis). The cereal-fiber and whole-grain associations were statistically clearer; fruit, vegetable and legume estimates were not significant. Confounding and dietary measurement error limit causal interpretation (BMJ fiber meta-analysis).
| Form | Evidence | Best use | Side effects | Interactions | Grade |
|---|---|---|---|---|---|
| Whole grains | Prospective observational studies associate higher intake with lower colorectal cancer risk. | Daily food pattern; replace refined grains when possible. | Gas, bloating, bowel changes if increased rapidly. | Generally food-safe; people with celiac disease must avoid gluten-containing grains. | Strong |
| Cereal fiber / bran foods | BMJ analysis found cereal fiber RR 0.90 per 10 g/day. | Part of a fiber-rich dietary pattern; cancer-risk findings are observational. | GI discomfort if increased quickly. | The cancer meta-analysis does not establish a broad medicine-absorption interaction for bran foods. | Strong |
| Psyllium or isolated fiber supplements | Psyllium treats constipation and is sometimes prescribed for diarrhea or high cholesterol. Food-pattern cancer associations do not establish psyllium prevention. Drug monograph | Use as directed for the relevant indication; take each dose with at least 8 oz/240 mL liquid. | Stomach pain, nausea, vomiting or difficulty swallowing require medical advice; use adequate liquid. | Do not take digoxin, salicylates or nitrofurantoin within 3 hours of psyllium; review other medicines with a pharmacist. | Moderate for health, indirect for cancer |
2. Cruciferous vegetables and sulforaphane
Verdict: OBSERVATIONAL FOOD EVIDENCE; supplement benefit unestablished
Cruciferous vegetables include broccoli, Brussels sprouts, cabbage, cauliflower, kale, bok choy, radish, arugula, and mustard greens; they contain glucosinolates that can yield isothiocyanates such as sulforaphane after chopping, chewing, or microbial metabolism (cruciferous vegetable review). The pooled observational estimate favored higher intake, but the prospective subgroup was weaker and borderline (RR 0.93, 95% CI 0.87–1.00). Case-control findings are more vulnerable to recall and selection bias; neither proves capsule efficacy (cruciferous vegetable meta-analysis).
| Form | What actually does the work | Evidence | Safety / interactions | Grade |
|---|---|---|---|---|
| Broccoli and broccoli sprouts | Glucoraphanin converted to sulforaphane. | The cited 2007 review describes mechanisms and human biomarkers; these do not establish supplement cancer prevention. | The cited review does not establish a complete food-safety or clinical drug-interaction profile; assess individual food and treatment needs. | Moderate as food |
| Cabbage, cauliflower, kale, Brussels sprouts | Glucosinolates, indoles, fiber, micronutrients. | Pooled observational association; the prospective colorectal subgroup was borderline. | Maintain consistent vitamin K intake when using warfarin or related vitamin K antagonists. NIH ODS | Moderate |
| Sulforaphane / broccoli sprout extract capsules | Standardized glucoraphanin or sulforaphane precursors. | Mechanisms and biomarkers in the cited historical review do not establish clinical prevention or treatment benefit. | Product composition varies; oncology drug interactions are not fully mapped. | Unproven supplement |
3. Vitamin D
Verdict: MIXED: correct deficiency; do not megadose for cancer prevention
Vitamin D is biologically relevant to cell growth and immune pathways, but supplementation did not reduce total invasive cancer incidence in the VITAL primary trial (VITAL primary trial). A secondary analysis reported fewer metastatic-or-fatal cancers as a composite (HR 0.83, 95% CI 0.69–0.99). The analyses were not corrected for multiple comparisons, and individual metastatic-cancer and cancer-death estimates were nonsignificant. The normal-BMI subgroup result is exploratory and does not justify a dosing rule; the authors call for confirmation (VITAL advanced-cancer analysis).
| Form | Evidence for cancer | Best use | Side effects | Interactions | Grade |
|---|---|---|---|---|---|
| Vitamin D3 / cholecalciferol | No lower invasive cancer incidence in VITAL; its secondary advanced-cancer composite is preliminary. | Correct low vitamin D status and support bone/mineral physiology. | Excess can cause hypercalcemia, nausea, weakness, constipation, kidney stones, and kidney injury. | ODS names orlistat, systemic corticosteroids and thiazides; thiazides can increase hypercalcemia risk. Review the exact regimen. NIH ODS | Mixed |
| Vitamin D2 / ergocalciferol | Vitamin D2 was not the VITAL intervention. Both D2 and D3 raise vitamin D status; this does not establish D2 cancer prevention. | Alternative for deficiency correction when appropriate. | Same toxicity pattern at excessive doses. | Same interaction categories as D3. | Mixed |
| Active vitamin D medicines / high-dose protocols | Not a wellness supplement; drug-like risk. | Clinician-directed medical indications only. | Do not extrapolate supplement-trial results to active medicines or self-prescribed high doses. | Requires medication review and calcium monitoring. | Do not self-dose |
4. Green tea and EGCG
Verdict: INCONCLUSIVE; beverage is different from high-dose extract
Green tea contains catechins such as EGCG, but Cochrane found inconsistent results and limited evidence for cancer prevention overall (Cochrane green tea review). High-dose green-tea extract is a safety concern because LiverTox reports clinically apparent acute liver injury, including rare liver failure, transplant, or death (LiverTox green tea).
| Form | Evidence | Safety | Interactions | Grade |
|---|---|---|---|---|
| Brewed green tea | Cancer-prevention beverage associations are inconsistent; extract RCTs do not establish the same beverage effect. | The cited liver chapter concerns liver injury, principally with extracts; it does not establish this table’s complete caffeine interaction profile. | Review the exact beverage intake and medicine regimen with the care team; the cited liver chapter does not verify a stimulant or warfarin interaction for every preparation. | Inconclusive |
| EGCG / green-tea extract capsules | No firm cancer-prevention recommendation. | Review the exact product and cancer regimen with the oncology team; avoid reexposure after suspected extract-related liver injury. | Avoid with liver disease or hepatotoxic medicines unless supervised; discuss during chemotherapy. | Higher-risk supplement |
Text version of this infographic
| Ingredient | Food form | Supplement form | Verdict |
|---|---|---|---|
| Fiber | Whole grains and cereal fiber have the strongest colorectal-risk evidence. | Fiber pills have more indirect cancer evidence. | Prefer food-first fiber. |
| Cruciferous vegetables | Broccoli, cabbage, kale, and related vegetables have observational support. | Sulforaphane capsules rely mostly on biomarker evidence. | Prefer cruciferous vegetables as foods. |
| Vitamin D | Food and sunlight contribute to status, but status varies by person. | Supplementation corrects deficiency; megadosing is not proven for broad cancer prevention. | Correct deficiency when clinically indicated; the cancer trials do not establish routine testing for everyone. |
| Green tea | Brewed tea evidence is inconclusive. | EGCG extract has liver-safety concerns. | Avoid high-dose extracts without medical supervision. |
Popular cancer ingredients that are unproven, debunked, or dangerous
Laetrile, amygdalin, vitamin B17, and apricot kernels
Laetrile/amygdalin is promoted under names such as “vitamin B17,” but Cochrane found no RCT or quasi-RCT evidence supporting it as cancer treatment and concluded the risk-benefit balance is unambiguously negative because of cyanide poisoning risk (Cochrane laetrile review). NCI’s reference summary reports no controlled clinical trial of laetrile and lists cyanide-like toxicity including liver damage, nerve damage, coma, and death (NCI laetrile PDQ).
High-dose intravenous vitamin C
High-dose IV vitamin C remains investigational rather than a general cancer cure. Oral vitamin C trials and IV regimens are not interchangeable. NCI’s current PDQ describes mixed newer adjunct trials, including a null prostate-cancer trial and a small positive pancreatic-cancer trial. In the latter, 34 treated participants received chemotherapy with or without IV ascorbate; survival favored the combination, but the unblinded phase II trial stopped early and needs larger confirmation. Original pancreatic trial reports NIH support and no known competing interests; complete product purchase/donation terms were not reported in the main paper. Do not replace oncology treatment with an infusion protocol.
Essiac and Flor Essence teas
Essiac and Flor Essence are proprietary herbal tea mixtures, and NCI’s reference summary states that no controlled human data show they are effective for cancer patients (NCI Essiac/Flor Essence PDQ). NCI also notes that some evidence suggested Flor Essence may increase tumor formation in an animal model of breast cancer, which makes “it is natural, so it cannot hurt” an unsafe assumption (NCI Essiac/Flor Essence PDQ).
Gerson therapy and coffee enemas
Gerson therapy combines a restrictive diet, supplements, pancreatic enzymes, and repeated coffee or other enemas; NCI’s reference summary states that no conclusions about effectiveness as an adjuvant or cure can be drawn from the reported studies (NCI Gerson PDQ). NCI summarizes three reported deaths: two were attributed to electrolyte imbalance, and one patient developed polymicrobial septicemia after clinic treatment. The latter death could not be directly linked to coffee enemas, and these reports do not establish an event rate (NCI Gerson PDQ).
Graviola / soursop
Graviola is marketed online as an anticancer botanical, but Memorial Sloan Kettering Cancer Center states there is no proof it benefits cancer patients and summarizes cell-line findings that do not establish patient tumor or survival benefit (MSKCC graviola). MSKCC also flags uncertainty about whether neurotoxicity seen in preclinical studies translates to humans, with clinical relevance unresolved. These findings do not justify cancer-treatment claims (MSKCC graviola).
Alkaline water and alkaline diets
The alkaline-water cancer claim is a chemistry-sounding story without clinical proof: a 2016 BMJ Open review searched through April 2015 and found no randomized trials and no alkaline-water cancer-treatment studies (BMJ Open alkaline-water review). The only included observational study concerned dietary acid load and bladder cancer, not an alkaline-water treatment trial. These historical findings do not justify treatment claims (BMJ Open alkaline-water review).
Hydrogen peroxide and “oxygen” therapies
Hydrogen peroxide and other “hyperoxygenation” therapies are based on the erroneous idea that cancer is caused by oxygen deficiency, according to the available abstract of a 1993 CA: A Cancer Journal for Clinicians review (hydrogen peroxide review). Cassileth’s 2009 publisher article states that oxygen therapies have no scientific evidence supporting cancer-cure claims and have caused serious adverse events and deaths (oxygen therapies article).
Text version of this infographic
| Remedy | Main evidence problem | Main risk |
|---|---|---|
| B17 / apricot kernels | No controlled clinical evidence for cancer treatment. | Cyanide poisoning, coma, death. |
| Hydrogen peroxide | No scientific evidence supporting cancer-cure claims. | Poisoning, gas embolism, serious adverse events, death. |
| Gerson therapy | No reliable conclusion about cancer effectiveness. | Electrolyte-imbalance deaths and a septicemia death reported; the latter was not directly linked to enemas. Event rates are unknown. |
| Essiac / Flor Essence | No controlled human efficacy data for cancer. | False reassurance; possible product variability and adverse effects. |
| Graviola / soursop | Laboratory findings do not establish cancer-patient tumor or survival benefit. | Neurotoxicity concerns and treatment delay. |
| Alkaline water | No alkaline-water cancer-treatment studies found in the review’s search through April 2015. | False reassurance and wasted time. |
What works and what does not
| Claimed benefit | Verdict | Evidence | Key caveat |
|---|---|---|---|
| Lower colorectal cancer risk with fiber/whole grains | ASSOCIATED WITH LOWER RISK | Prospective meta-analysis with dose response. | Food pattern evidence; not a treatment for existing cancer. |
| Lower colorectal cancer risk with cruciferous vegetables | LIMITED OBSERVATIONAL SUPPORT | Pooled observational estimate favors higher intake, but prospective findings are weaker; mechanisms do not prove efficacy. | Not proof that sulforaphane capsules prevent cancer. |
| Prevent cancer with vitamin D supplements | MIXED | VITAL null for invasive cancer; secondary advanced-cancer signal. | The unconfirmed secondary signal does not prescribe a dose for patients with cancer; correct deficiency for nutritional indications. |
| Prevent cancer with green tea / EGCG | INSUFFICIENT | Cochrane found inconsistent, low-certainty evidence. | High-dose extracts can injure the liver. |
| Slow or treat cancer with curcumin | DOES NOT HAVE PROOF | The 2023 review found mixed small-trial findings insufficient for routine therapy, including one IV formulation and a precancer study. | Discuss exact formulation and regimen with the oncology team; turmeric supplements can cause liver injury. |
| Prevent cancer with omega-3 supplements | DOESN’T | Long-chain omega-3 pooled estimates were null for cancer diagnosis (27 trials) and cancer death (18 trials), within a 47-trial all-PUFA review. | Omega-3 may have other indications, but cancer prevention is not one. |
| Treat cancer with laetrile/B17/apricot kernels | DANGEROUS | Cochrane found no supportive RCT evidence and cyanide poisoning risk. | Avoid entirely. |
| Treat cancer with alkaline water | NO EVIDENCE | The 2016 review found no treatment studies in its search through April 2015. | Do not use pH claims to delay care. |
| Treat cancer with Gerson, Essiac, graviola, or peroxide | AVOID AS TREATMENT | NCI, MSKCC, and PubMed reviews find no adequate treatment evidence and safety concerns. | Especially dangerous when substituted for oncology treatment. |
Side effects and interactions
People in active cancer treatment should treat supplements like medication exposures because herbs, vitamins, antioxidants, and concentrated extracts can interact with some cancer treatments. The exact product, dose and regimen determine the concern; these overview pages do not establish every proposed anticoagulation, anesthesia or immunotherapy interaction (NCCIH cancer and complementary approaches, NCI CAM overview). The interaction table below is not a substitute for an oncology pharmacist review.
| Ingredient | Symptoms / frequency limits | Rare but serious risks | Interaction evidence and limits | Who should be extra cautious | Source |
|---|---|---|---|---|---|
| Fiber / psyllium | Frequency is not quantified here. Stomach pain, nausea or vomiting warrant medical advice. | Choking or obstruction if taken dry or with too little fluid. | Do not take digoxin, salicylates or nitrofurantoin within 3 hours of psyllium; review all other medicines individually. | Swallowing difficulty or intestinal blockage; ask the care team when fluid intake is restricted. | MedlinePlus psyllium |
| Cruciferous vegetables / sulforaphane | Gas, bloating, taste intolerance. | The cited sources do not quantify a generic thyroid or raw-sprout risk for every cancer patient. | High vitamin K foods require consistency with warfarin; supplement interactions with oncology drugs are incompletely studied. | People using warfarin or related vitamin K antagonists should maintain consistent intake. Assess extract use with the oncology team. | NIH ODS vitamin K for warfarin consistency; oncology review for extract interactions. |
| Vitamin D | Nausea, constipation, weakness, thirst, frequent urination when excessive. | Hypercalcemia, kidney stones, kidney injury, arrhythmia risk in susceptible people. | Thiazides can increase hypercalcemia risk; orlistat can reduce absorption and systemic steroids can impair vitamin D metabolism. Review the actual regimen. | Discuss high doses with the care team, especially with impaired kidney function or hyperparathyroidism. | NIH ODS |
| Green tea beverage / EGCG extract | Caffeine effects, reflux, insomnia, nausea. | Green-tea extract can cause clinically apparent liver injury, rarely liver failure or transplant. | Caffeine effects and other medication questions require drug-specific review; this LiverTox chapter establishes liver injury, rather than a quantified warfarin interaction. Avoid combining hepatotoxic products without clinician review. (Primary source) | Prior extract-related liver injury: avoid reexposure. Review liver disease and the exact treatment regimen with a clinician. | LiverTox |
| Curcumin / turmeric extract | Nausea, reflux, stomach upset, diarrhea, constipation. | Turmeric products have been implicated in clinically apparent acute liver injury. | Drug-specific oncology review is required; the cited sources do not establish a clinical bleeding or diabetes-drug effect for every turmeric formulation. Bioavailability-enhanced products have liver-safety concerns. | Prior turmeric-related liver injury: avoid reexposure. NCCIH cautions that supplement use during pregnancy may be unsafe; discuss medicine use with a clinician. | NCCIH / LiverTox |
| Omega-3 EPA/DHA | Fishy burps, nausea, loose stools, reflux. | Trials of 4 g/day for several years in people with cardiovascular disease or high risk reported an atrial-fibrillation signal. Most summarized trials did not show clinically important bleeding. | Warfarin users may need INR monitoring. ODS notes that most studies did not find a significant anticoagulant effect at 3–6 g/day fish oil; review the exact product and medicines. | People with atrial fibrillation or using warfarin should review dose and indication with their clinician. | NIH ODS |
| Laetrile / B17 / apricot kernels | Nausea, vomiting, headache, dizziness. | Cyanide poisoning, liver damage, nerve injury, coma, death. | Risk is greater with oral use; high-dose oral vitamin C and raw almonds/crushed fruit pits can worsen cyanide toxicity. | Everyone; avoid entirely. | Cochrane/PMC |
| Gerson therapy / coffee enemas | The cited PDQ provides case reports rather than reliable frequencies for diarrhea, dehydration or other symptoms. | Two deaths were attributed to electrolyte imbalance; a septicemia death could not be directly linked to enemas. Rates are unknown. | Can destabilize electrolytes and interfere with treatment nutrition plans. | People with cancer should not substitute this regimen for oncology treatment; individualized vulnerability requires clinical assessment. | NCI PDQ |
Text version of this infographic
| Checkpoint | Why it matters | Examples |
|---|---|---|
| Blood thinners | Some supplements may affect bleeding risk or vitamin K consistency. | Warfarin, DOACs, aspirin, clopidogrel. |
| Cancer therapies | Some supplements can interact with cancer treatment; effects and trial rules depend on the exact regimen. | Antioxidant megadoses, botanicals, unknown extracts. |
| Liver/kidney risks | Concentrated extracts and megadoses can injure detoxification and excretion pathways. | EGCG extract, curcumin extract, vitamin D megadoses. |
| Surgery/procedures | Tell the treatment team about all products before a procedure; precautions depend on the product and procedure. | Review every product rather than treating fish oil or turmeric as a universal procedure contraindication. |
Funding and conflict review
Research funding at a glance
9 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
| Source | Disclosures and limits | Credibility rank | Money trail / influence check | Why it may be reliable |
|---|---|---|---|---|
| BMJ fiber and whole-grain meta-analysis | Review support disclosed; cohort finances incomplete | Very strong | WCRF grant 2007/SP01; authors declared no interested-organization financial relationships. They stated the sponsor had no study/manuscript role. Every cohort’s finances were not traced. | Prospective studies and dose-response methods; residual confounding and diet measurement error remain. |
| Cruciferous vegetable colorectal-cancer meta-analysis | Review disclosures read; included-study finances incomplete | Strong | Public academic and NIH-linked training funding; authors declared no conflicts. | Design-stratified findings are more informative than the pooled estimate; prospective colorectal findings were weaker and borderline. |
| VITAL primary trial and advanced-cancer analysis | Partly conflicted but high-quality | Strong | NIH grants supported VITAL. Pharmavite and Pronova/BASF donated agents, placebos and calendar packaging; Quest provided assays at no cost. The advanced-cancer paper disclosed Buring’s spouse on Pharmavite’s advisory board. Exact support values were not reported. | Large randomized prevention trial with a null primary cancer endpoint. The advanced-cancer composite and BMI subgroup remain preliminary secondary findings; a null result does not remove financial ties. |
| Cochrane green tea review | Review disclosures read; included-trial ties vary | Strong | Pilkington Family Trusts, Deutsche Krebshilfe and Cochrane/ViFab support; review interests “none known.” Trial notes name Mitsui-Norin product supply, Sofar free samples, Genprofiler support and an Ito En employee. Complete funding/procurement chains were not cleared. | Cochrane methods explicitly graded uncertainty and did not overstate benefits. |
| Omega-3 randomized-trial meta-analysis | WHO support/role disclosed; trial finances incomplete | Very strong | WHO project HQNHD1612458 funded the review and meeting travel. WHO requested inclusion criteria and some analyses; authors declared no interested-organization relationships. Included-trial finances were not exhaustively traced. | Randomized prevention evidence with defined endpoints; several-year trials may not capture cancer effects with long latency. |
| Curcumin cancer RCT review | Review declares no external funding/conflicts; trial finances incomplete | Strong | No external funding; authors declared no conflict of interest. | Examined hard endpoints, but only seven heterogeneous trials, mixed routes/populations and some biased or underpowered studies were available. |
| Cochrane laetrile review | Public/charitable review support disclosed | Very strong | NIHR/Cochrane infrastructure; European Commission CAM-Cancer grant and Deutsche Krebshilfe/KOKON support. Authors declared no direct financial interest; funders reportedly had no design/conduct/writing role. | Strong negative conclusion matches NCI clinical-trial history and toxicity evidence. |
| NCI PDQ Gerson summary | Public editorial resource; underlying finances not fully traced | Strong | NCI-hosted PDQ literature summary with an editorial board independent of NCI policy; the page is now retained for reference and no longer updated. Complete board and underlying-study finances were not verified. | Institutional accountability and explicit adverse-event reporting. |
| BMJ Open alkaline-water review | No specific grant/conflicts declared; underlying-study finances incomplete | Strong | No specific grant; competing interests none declared. | Explicit systematic search through April 2015; one acid-load cohort, no alkaline-water treatment study. This is historical search evidence. |
Frequently asked questions
What supplement is proven to prevent cancer?
No supplement in this review is proven to broadly prevent cancer. Prospective dietary studies associate fiber and whole grains with lower colorectal cancer risk as part of a food pattern, not as a cancer-treatment capsule (BMJ fiber meta-analysis).
Can sulforaphane or broccoli sprouts treat cancer?
The cited 2007 review describes plausible mechanisms and human biomarkers; it does not establish sulforaphane treatment or supplement prevention. Food-pattern associations are a different question, and this historical review is not an exhaustive current trial search (cruciferous vegetable review).
Should people with cancer take vitamin D?
Vitamin D should be used to correct deficiency or support bone/mineral health when clinically appropriate, not as a standalone cancer treatment. VITAL was a prevention trial in participants initially free of cancer, not a treatment or deficiency-dose trial. It found no significant reduction in invasive cancer incidence; the secondary advanced-cancer composite remains preliminary. It does not prescribe vitamin D for a patient with cancer (VITAL primary trial, VITAL advanced-cancer analysis).
Is green tea safe during cancer treatment?
Brewed green tea is not the same as concentrated EGCG extract. Green-tea extract has been linked to liver injury in LiverTox, and NCCIH advises people with cancer to consult their health care providers before adding supplements or complementary approaches (LiverTox green tea, NCCIH cancer and complementary approaches).
Does curcumin fight cancer?
Curcumin has extensive laboratory interest but limited human cancer evidence. A 2023 review of seven heterogeneous trials found the evidence insufficient for routine therapy. It included adjunct treatments, one IV formulation and a precancer condition, with some positive small-study signals; it does not establish a general cancer cure (curcumin RCT review).
Do omega-3 supplements reduce cancer risk?
The reviewed randomized evidence does not support omega-3 supplements for cancer prevention. A review of 47 trials across several PUFA interventions found little or no effect for long-chain omega-3 on cancer diagnosis (27 trials) or cancer death (18 trials) (omega-3 randomized-trial meta-analysis).
Is vitamin B17 the same as laetrile or apricot kernels?
“Vitamin B17” is a marketing name commonly used for amygdalin/laetrile-related products, including apricot-kernel products. Cochrane found no supportive RCT evidence for cancer treatment and warned about cyanide poisoning risk (Cochrane laetrile review).
Does alkaline water kill cancer cells?
The cited historical review does not support alkaline water as cancer therapy. The 2016 BMJ Open review found no randomized trials and no alkaline-water cancer-treatment studies in its search through April 2015; that search does not establish absence of all later research (BMJ Open alkaline-water review).
Why are testimonials not enough for cancer remedies?
Cancer outcomes can be affected by diagnosis accuracy, stage, concurrent treatment, imaging timing, tumor biology, and spontaneous symptom changes. NCI notes that anecdotal and case reports for laetrile provide little evidence because of mixed conventional therapies, variable dose and duration, and inconsistent documentation (NCI laetrile PDQ).
What should a patient do before taking any supplement during cancer care?
Bring the exact product label, dose, frequency, and reason for use to the oncology team or oncology pharmacist. NCCIH warns that some complementary approaches can interfere with cancer treatment and says people diagnosed with cancer should consult health care providers before using them (NCCIH cancer and complementary approaches).
Sources
- Aune D, Chan DSM, Lau R, et al. Dietary fibre, whole grains, and risk of colorectal cancer: systematic review and dose-response meta-analysis of prospective studies. BMJ. 2011. https://www.bmj.com/content/343/bmj.d6617
- Wu QJ, Yang Y, Vogtmann E, et al. Cruciferous vegetables intake and the risk of colorectal cancer: a meta-analysis of observational studies. Annals of Oncology. 2013. https://pmc.ncbi.nlm.nih.gov/articles/PMC3603442/
- Higdon JV, Delage B, Williams DE, Dashwood RH. Cruciferous vegetables and human cancer risk: epidemiologic evidence and mechanistic basis. Pharmacological Research. 2007. https://pmc.ncbi.nlm.nih.gov/articles/PMC2737735/
- Manson JE, Cook NR, Lee IM, et al. Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. New England Journal of Medicine. 2019. https://pubmed.ncbi.nlm.nih.gov/30415629/
- Chandler PD, Chen WY, Ajala ON, et al. Effect of Vitamin D3 Supplements on Development of Advanced Cancer. JAMA Network Open. 2020. https://pmc.ncbi.nlm.nih.gov/articles/PMC7675103/
- NIH Office of Dietary Supplements. Vitamin D — Health Professional Fact Sheet. https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/
- Filippini T, Malavolti M, Borrelli F, et al. Green tea (Camellia sinensis) for the prevention of cancer. Cochrane Database of Systematic Reviews. 2020. https://pmc.ncbi.nlm.nih.gov/articles/PMC7059963/
- LiverTox. Green Tea. NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK547925/
- de Waure C, Bertola C, Baccarini G, Chiavarini M, Mancuso C. Exploring the Contribution of Curcumin to Cancer Therapy: A Systematic Review of Randomized Controlled Trials. 2023. Research record
- NCCIH. Turmeric: Usefulness and Safety. https://www.nccih.nih.gov/health/turmeric
- LiverTox. Turmeric. NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK548561/
- Hanson S, Thorpe G, Winstanley L, et al. Omega-3, omega-6 and total dietary polyunsaturated fat on cancer incidence: systematic review and meta-analysis of randomised trials. British Journal of Cancer. 2020. https://pmc.ncbi.nlm.nih.gov/articles/PMC7156752/
- NIH Office of Dietary Supplements. Omega-3 Fatty Acids — Health Professional Fact Sheet. https://ods.od.nih.gov/factsheets/Omega3FattyAcids-HealthProfessional/
- Milazzo S, Horneber M. Laetrile treatment for cancer. Cochrane Database of Systematic Reviews. 2015. https://pmc.ncbi.nlm.nih.gov/articles/PMC6513327/
- NCI PDQ. Laetrile/Amygdalin. https://www.cancer.gov/about-cancer/treatment/cam/hp/laetrile-pdq
- NCI PDQ. Intravenous Vitamin C. https://www.cancer.gov/about-cancer/treatment/cam/hp/vitamin-c-pdq
- NCI PDQ. Essiac/Flor Essence. https://www.cancer.gov/about-cancer/treatment/cam/hp/essiac-pdq
- NCI PDQ. Gerson Therapy. https://www.cancer.gov/about-cancer/treatment/cam/hp/gerson-pdq
- Memorial Sloan Kettering Cancer Center. Graviola. https://www.mskcc.org/cancer-care/integrative-medicine/herbs/graviola
- Fenton TR, Huang T. Systematic review of the association between dietary acid load, alkaline water and cancer. BMJ Open. 2016. https://pmc.ncbi.nlm.nih.gov/articles/PMC4916623/
- Green S. Questionable methods of cancer management: hydrogen peroxide and other “hyperoxygenation” therapies. CA: A Cancer Journal for Clinicians. 1993. https://pubmed.ncbi.nlm.nih.gov/8422605/
- Cassileth B. Oxygen therapies. Oncology. 2009. https://www.cancernetwork.com/view/oxygen-therapies
- NCCIH. Cancer and Complementary Health Approaches: What You Need To Know. https://www.nccih.nih.gov/health/cancer-and-complementary-health-approaches-what-you-need-to-know
- NCI. Complementary and Alternative Medicine. https://www.cancer.gov/about-cancer/treatment/cam
- WHO. Cancer fact sheet. https://www.who.int/news-room/fact-sheets/detail/cancer
- IARC. IARC Monographs evaluate consumption of red meat and processed meat. https://www.iarc.who.int/wp-content/uploads/2018/07/pr240_E.pdf
Trust and disclosure footer
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.